Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PYPD
PYPD logo

PYPD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy PolyPid Ltd (PYPD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.580
1 Day change
52 Week Range
5.120
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

PolyPid Ltd (PYPD) is not a strong buy at the moment given the lack of positive financial performance, absence of significant trading trends, and no recent news or catalysts. While technical indicators suggest a mildly bullish trend, the company's financials and lack of significant trading sentiment do not support a compelling long-term investment opportunity for a beginner investor with $50,000-$100,000 to invest.

Technical Analysis

The stock shows a mildly bullish trend with MACD above zero and positively contracting, RSI in the neutral zone at 56.638, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 4.548, R1: 4.754, S1: 4.341, R2: 4.881, S2: 4.214.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
6

Positive Catalysts

  • NULL identified. No recent news, significant trading trends, or influential figure activity.

Neutral/Negative Catalysts

  • No recent congress trading data or news events to drive sentiment.

Financial Performance

In Q4 2025, revenue remained at 0 with no growth YoY. Net income dropped to -$8,473,000 (-0.55% YoY), and EPS declined significantly by -63.72% YoY to -0.41. Gross margin remained at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast PYPD stock price to rise
3 Analyst Rating
Wall Street analysts forecast PYPD stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.580
sliders
Low
9
Averages
11
High
13
Current: 4.580
sliders
Low
9
Averages
11
High
13
Roth Capital
Buy
downgrade
$10 -> $9
AI Analysis
2025-11-13
Reason
Roth Capital
Price Target
$10 -> $9
AI Analysis
2025-11-13
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 "enjoys multiple designations" from the FDA, it should get a six-month review, the analyst tells investors in a research note.
Roth Capital
Buy
maintain
$9 -> $10
2025-08-14
Reason
Roth Capital
Price Target
$9 -> $10
2025-08-14
maintain
Buy
Reason
Roth Capital raised the firm's price target on PolyPid to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company's Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PYPD
Unlock Now

People Also Watch